Table 2.
Characteristics of industry-sponsored clinical trials performed exclusively within one major geographic group a
| Study characteristic | Major geographic group | ||||
|---|---|---|---|---|---|
| Americas N = 406 | Middle East/Africa N = 163 | Asia N = 1138 | Europe (non-Western) N = 256 | High-income regions N = 16,246 | |
| Median study sites, N (IQR) | 1 c | 1 c | 1 c | 2 c | 1 |
| (1–2) | (1–3) | (1–4) | (1–9) | (1–9) | |
| Median subjects enrolled, N (IQR) | 100 c | 183 c | 142 c | 120 c | 71 |
| (48–200) | (90–400) | (50–300) | (47–259) | (33–188) | |
| Double-blinded, N (%) | 191 c | 73 c | 502 c | 168 | 9938 |
| (46.9) | (44.7) | (44.1) | (65.6) | (61.1) | |
| Industry as lead funder, N (%) | 345 c | 115 c | 998 c | 236 c | 13 133 |
| (84.8) | (70.5) | (87.7) | (92.2) | (80.8) | |
| Phase 3 or 4, N (%) | 250 c | 73 c | 589 c | 104 c | 5345 |
| (61.6) | (44.7) | (51.7) | (40.6) | (32.9) | |
| Paediatric b N (%) | 42 c | 51 c | 120 c | 28 c | 699 |
| (10.3) | (31.3) | (10.5) | (10.9) | (4.2) | |
a 18,209 (80.9 %) of all trials were conducted exclusively in one region and are included in the table
b Defined as listed maximum age <19, or if listed maximum age above 19, median age <19. If no maximum age listed, trial assumed to be adult
c P <0.05 by χ 2 or Mann–Whitney testing when compared with high-income regions